15 completed, 5 unknown, 4 terminated, 3 not yet recruiting. 14 Phase 2, 12 Phase 1, 2 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Plasmacytoma: new trials by email Literature Review of Plasmacytoma trials Research Report on Plasmacytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-08-27 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| T-cell Receptor α/β Depleted Donor Lymphocyte Infusion T-cell Receptor α/β Depleted Donor Lymphocyte Infusions - Lymphoid Leukemia, Acute, Myeloid Malignancy | Phase 1 | Terminated | Guenther Koehne | 11 | 2022-04-05 | 2024-12-10 |
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Plasma Cell Tumors | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 60 | 2020-10-22 | 2020-12-11 |
| A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma CC-486, Lenalidomide, Radiation Therapy - Plasmacytoma, Plasmacytoma of Bone | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 21 | 2019-11-19 | 2025-12-02 |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma BCMA-PD1-CART Cell - Multiple Myeloma | Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2019-07-07 | 2019-11-18 |
| Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma Drug Combinations - Multiple Myeloma in Relapse, Plasmacytoma | Phase 2 | Unknown | Seoul National University Hospital | 33 | 2019-01-14 | 2019-08-22 |
| The Indiana Myeloma Registry This is a non-interventional trial - Plasma Cell Dyscrasias | Recruiting | Indiana University | 2500 | 2018-06-18 | 2025-11-10 | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib - Plasmacytoma, Recurrent Multiple Myeloma | Phase 1 | Terminated | National Cancer Institute (NCI) | 35 | 2018-06-14 | 2026-02-10 |
| Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma SBRT - Plasmacytoma | Phase 2 | Terminated | Instituto do Cancer do Estado de São Paulo | 10 | 2017-10-01 | 2022-04-06 |
| Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Lenalidomide, Dexamethasone, No further treatment - Plasmacytoma | Phase 3 | Active not recruiting | University College, London | 36 | 2017-03-10 | 2022-12-23 |
| Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Dexamethasone, Ixazomib Citrate, Lenalidomide - Plasmacytoma, POEMS Syndrome | Early Phase 1 | Completed | Mayo Clinic | 21 | 2016-10-31 | 2025-02-12 |
| The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures Vertebral Compression Fracture, Myeloma | Completed | Centre Hospitalier Universitaire de Nice | 1120 | 2016-01-01 | 2023-12-11 | |
| Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis - Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 17 | 2015-12-24 | 2023-10-30 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride - Plasma Cell Leukemia, Plasmacytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 83 | 2015-09-14 | 2025-03-18 |
| Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Daratumumab, VELCADE (Bortezomib), Dexamethasone - Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 498 | 2014-08-15 | 2025-08-29 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer sodium selenite, radiation therapy, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1 | Completed | Stanford University | 15 | 2014-07-01 | 2024-05-28 |
| Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting Pomalidomide, Dexamethasone, Daratumumab - Multiple Myeloma | Phase 2 | Completed | Celgene | 186 | 2014-05-29 | 2026-06-15 |
| Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy Carcinoma | Unknown | SPGO Research Mannheim GmbH | 2000 | 2013-10-01 | 2017-02-24 |
Showing 20 of 30. Sign in to see all of them.
Multiple Myeloma (22) · Leukemia, Plasma Cell (4) · Paraproteinemias (3) · Breast Neoplasms (2) · Neoplasms, Plasma Cell (2) · Prostatic Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Disease (1) · Endometriosis (1) · Head and Neck Neoplasms (1)
Immune System Diseases (30) · Immunoproliferative Disorders (30) · Lymphoproliferative Disorders (30) · Neoplasms by Histologic Type (30) · Neoplasms (29) · Neoplasms, Plasma Cell (28) · Hemic and Lymphatic Diseases (25) · Hematologic Diseases (24) · Blood Protein Disorders (23) · Cardiovascular Diseases (22) · Hemorrhagic Disorders (22) · Hemostatic Disorders (22) · Vascular Diseases (22) · Paraproteinemias (20) · Leukemia (5)
Dexamethasone (8) · Lenalidomide (4) · Bortezomib (3) · Calcium Dobesilate (3) · auricularum (3) · daratumumab (3) · dexamethasone 21-phosphate (3) · dexamethasone acetate (3) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Injections, Subcutaneous (2) · Radiotherapy (2) · Steroids (2) · filanesib (2) · ixazomib (2)
Mayo Clinic (2) · Shenzhen Geno-Immune Medical Institute (2) · University of Arkansas (2) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Celgene (1) · Centre Hospitalier Universitaire de Nice (1) · Chinese PLA General Hospital (1) · Cylene Pharmaceuticals (1) · Gilead Sciences (1) · Guenther Koehne (1) · Hebei Senlang Biotechnology Inc., Ltd. (1) · Indiana University (1) · Instituto do Cancer do Estado de São Paulo (1) · Janssen Research & Development, LLC (1) · M.D. Anderson Cancer Center (1)
United States (17) · China (4) · Germany (4) · Brazil (2) · South Korea (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · Puerto Rico (1)
Andrzej J. Jakubowiak, MD, PhD (1) · Angela Dispenzieri, M.D. (1) · Athanasios Fassas, MD (1) · Attaya Suvannasankha, MD (1) · Baoen Shan, PhD & MD (1) · Guenther Koehne, MD, PhD (1) · Hans C Lee (1) · Janet S. Biermann, MD (1) · Lihong Liu, PhD & MD (1) · Lixun Guan (1) · Lu Wang (1)
PMID 16229966, PMID 17032388, PMID 18725106, PMID 20952514, PMID 23078786, PMID 24112026, PMID 24773479, PMID 25987031, PMID 27557302, PMID 28817190, PMID 31221782, PMID 31588567, PMID 32819447, PMID 32928795, PMID 33513030, PMID 34289038, PMID 35133221, PMID 35876974, PMID 36413710, PMID 38048391, PMID 39229471, PMID 6153562, PMID 6780494
2014 (1), P30CA124435 (1), U10CA032102 (1), UM1CA186688 (1)